The aim of this study was to determine the frequency of ROS1 and RET rearrangements and their relationship with clinicopathological characteristics in resected stage IIIA-N2 NSCLC and to provide guidance for future clinical treatment. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.